Shares of VYNE Therapeutics (NASDAQ: VYNE) were crashing 18.1% lower as of 11:35 a.m. EDT on Thursday. VYNE reported Q1 revenue of $4.1 million, up from $1.8 million in the prior-year period. VYNE launched Zilxi in October 2020 after receiving approval earlier that year by the U.S. Food and Drug Administration (FDA) for the drug in treating rosacea.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting